Neurogene Prices $125M Public Offering at $30/Share, Extends Cash Runway

summarizeSummary

Neurogene Inc. finalized a public offering of common stock and pre-funded warrants, raising $117.2 million at $30.00 per share, significantly extending its cash runway into Q3 2028.

check_boxKey Events · Financing and Capital Events · NGNE

• Public Offering Priced

  Neurogene Inc. priced its public offering of 3,500,000 shares of common stock and pre-funded warrants to purchase 666,666 shares of common stock at $30.00 per share/warrant.

• Significant Capital Raise

  The offering is expected to generate approximately $117.2 million in net proceeds for the company, potentially increasing to $134.8 million if underwriters fully exercise their option for additional shares.

• Extended Cash Runway

  The proceeds, combined with existing cash, are projected to fund operations into the third quarter of 2028, extending the previous estimate of Q1 2028.

• Dilutive at a Discount

  The offering price of $30.00 per share is at a discount to the last reported sale price of $31.45 on June 30, 2026, and the offering represents a substantial increase in outstanding shares.

auto_awesomeAnalysis · NGNE · Life Sciences

Neurogene Inc. has finalized the terms of its public offering, raising approximately $117.2 million in net proceeds by selling 3.5 million shares of common stock and pre-funded warrants for an additional 666,666 shares at $30.00 per share. This significant capital raise, representing over 20% of the company's market capitalization, is crucial for funding the ongoing clinical development of its lead gene therapy NGN-401 and extending its cash runway from Q1 2028 to Q3 2028. While the offering is dilutive and priced at a discount to recent market levels, it provides essential financial stability following positive clinical data for NGN-401.